Oxymetazoline hydrochloride
- CAS No.
- 2315-02-8
- Chemical Name:
- Oxymetazoline hydrochloride
- Synonyms
- OXYMETAZOLINE HCL;2-(4-t-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoliniumchloride;afrazine;duration;neonabel;AKOS 92115;Oxrmetazoline;afrinhydrochloride;iliadinhydrochloride;nafrinehydrochloride
- CBNumber:
- CB7157390
- Molecular Formula:
- C16H25ClN2O
- Molecular Weight:
- 296.84
- MDL Number:
- MFCD00797520
- MOL File:
- 2315-02-8.mol
| Melting point | approximate 300℃ (dec.) |
|---|---|
| storage temp. | Store at RT |
| solubility | H2O: soluble |
| form | solid |
| color | white |
| PH | pH (50g/L, 25℃) : 4.0～6.5 |
| Water Solubility | Soluble to 50 mM in water |
| Stability | Toxic |
| CAS DataBase Reference | 2315-02-8(CAS DataBase Reference) |
| FDA 21 CFR | 341.20 |
| EWG's Food Scores | 1 |
| FDA UNII | K89MJ0S5VY |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS05,GHS06 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H300+H330-H318-H412 | |||||||||
| Precautionary statements | P260-P264-P273-P280-P304+P340+P310-P305+P351+P338 | |||||||||
| Hazard Codes | T+ | |||||||||
| Risk Statements | 28 | |||||||||
| Safety Statements | 22-28-36/37/39-45 | |||||||||
| RIDADR | UN 2811 6.1/PG 1 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | SK1225000 | |||||||||
| HazardClass | 6.1(a) | |||||||||
| PackingGroup | II | |||||||||
| HS Code | 2933290000 | |||||||||
| Toxicity | LD50 orally in mice: 10 mg/kg (Hotovy) | |||||||||
| NFPA 704 |
|
Oxymetazoline hydrochloride Chemical Properties,Uses,Production
Chemical Properties
Off-White Solid
Originator
Nasivin,Merck,W. Germany ,1961
Uses
muscle relaxant (smooth), cerebral vasodilator
Uses
Oxymetazoline hydrochloride is an α1-AR and α2-AR adrenergic receptor agonist and used as Vasoconstrictor, a nasal decongestant.
Uses
Vasoconstrictor, used as a nasal decongestant. An ingredient of Drixin.
Definition
ChEBI: A hydrochloride salt resulting from the reaction of equimolar quantities of oxymetazoline and hydrogen chloride. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used to relieve nasal con estion.
Manufacturing Process
10 grams 2,6-dimethyl-3-hydroxy-4-tertiary butylbenzylcyanide (produced by chloromethylation of 2,4-dimethyl-6-tertiary butyl-phenol with formaldehyde and HCl and conversion of the substituted benzyl chloride with NaCN; crystals, from alcohol, melting at 135° to 137°C) and 10.7 grams ethylenediaminemono-p-toluenesulfonate are heated in an oil bath to approximately 235°C for 1? hours, whereby ammonia is evolved. The free base is obtained from the p-toluene-sulfonic acid imidazoline salt which is difficultly soluble in water, by conversion with 50 cc of a 10% NaOH solution. Said base is recrystallized from benzene, and 7.5 grams (62% of the theoretical yield) 2-(2',6'-dimethyl3'-hydroxy-4'-tertiary butylbenzyl)-2-imidazoline, MP 180° to 182°C, are obtained.
By dissolving the free base in an ethyl alcohol solution of hydrochloric acid and adding ether, the hydrochloride can be produced in the usual manner. Said hydrochloride melts, when recrystallized from alcoholic ether, at 300° to 303°C and is decomposed
brand name
Ocuclear (Schering-Plough); Visine (Pfizer).
Therapeutic Function
Nasal decongestant
Biological Activity
Partial α 2A adrenoceptor agonist and α 1A agonist. Agonist/antagonist activity at 5-HT receptors.
Oxymetazoline hydrochloride Preparation Products And Raw materials
Raw materials
1of2